Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an Gene Fusion

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2018 Mar 13

PMID 29527595

Citations 43

Authors

Kurtis D Davies

Terry L Ng

Adriana Estrada-Bernal

Anh T Le

Peter R Ennever

D Ross Camidge

Robert C Doebele

Dara L Aisner

Affiliations

Soon will be listed here.

Citing Articles

Remarkable response to capmatinib in a patient with intrahepatic cholangiocarcinoma harboring - fusion.

Ueta A, Yamada A, Yoshioka M, Kanai M, Muto M, Okita N Int Cancer Conf J. 2024; 13(3):199-203.

PMID: 38962049 PMC: 11217255. DOI: 10.1007/s13691-024-00664-8.

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers.

Cheong T, Jang A, Wang Q, Leonardi G, Ricciuti B, Alessi J Nat Commun. 2024; 15(1):5110.

PMID: 38877018 PMC: 11178778. DOI: 10.1038/s41467-024-49499-0.

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.

Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica J JTO Clin Res Rep. 2024; 5(2):100637.

PMID: 38361741 PMC: 10867444. DOI: 10.1016/j.jtocrr.2024.100637.

MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.

Yuan P, Xue X, Qiu T, Ying J Ther Adv Med Oncol. 2024; 16:17588359231221910.

PMID: 38249331 PMC: 10798113. DOI: 10.1177/17588359231221910.

MET fusions are targetable genomic variants in the treatment of advanced malignancies.

Sun D, Xing X, Wang Y, Hou H Cell Commun Signal. 2024; 22(1):20.

PMID: 38195556 PMC: 10775437. DOI: 10.1186/s12964-023-01454-0.

References

Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A . Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A. 2001; 98(26):15203-8. PMC: 65007. DOI: 10.1073/pnas.261414598. View

Vaishnavi A, Schubert L, Rix U, Marek L, Le A, Keysar S . EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017; 77(13):3551-3563. PMC: 5516930. DOI: 10.1158/0008-5472.CAN-17-0109. View

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

Tabernero J, Bahleda R, Dienstmann R, Infante J, Mita A, Italiano A . Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2015; 33(30):3401-8. DOI: 10.1200/JCO.2014.60.7341. View

Stransky N, Cerami E, Schalm S, Kim J, Lengauer C . The landscape of kinase fusions in cancer. Nat Commun. 2014; 5:4846. PMC: 4175590. DOI: 10.1038/ncomms5846. View

Awad M . Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(8):879-81. DOI: 10.1200/JCO.2015.64.2777. View

Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch K . Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014; 20(12):1479-84. DOI: 10.1038/nm.3729. View

Frampton G, Ali S, Rosenzweig M, Chmielecki J, Lu X, Bauer T . Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015; 5(8):850-9. DOI: 10.1158/2159-8290.CD-15-0285. View

Paik P, Drilon A, Fan P, Yu H, Rekhtman N, Ginsberg M . Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015; 5(8):842-9. PMC: 4658654. DOI: 10.1158/2159-8290.CD-14-1467. View

10.

Shim H, Kenudson M, Zheng Z, Liebers M, Cha Y, Hoang Ho Q . Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2015; 10(8):1156-62. DOI: 10.1097/JTO.0000000000000579. View

11.

Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius K, Jarvius J . Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006; 3(12):995-1000. DOI: 10.1038/nmeth947. View

12.

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

13.

Zou H, Li Q, Lee J, Arango M, McDonnell S, Yamazaki S . An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007; 67(9):4408-17. DOI: 10.1158/0008-5472.CAN-06-4443. View

14.

Lindeman N, Cagle P, Beasley M, Chitale D, Dacic S, Giaccone G . Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular.... J Mol Diagn. 2013; 15(4):415-53. DOI: 10.1016/j.jmoldx.2013.03.001. View

15.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M . Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016; 17(12):1653-1660. PMC: 5143197. DOI: 10.1016/S1470-2045(16)30562-9. View

16.

Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23(6):703-713. PMC: 5461196. DOI: 10.1038/nm.4333. View

17.

Farago A, Le L, Zheng Z, Muzikansky A, Drilon A, Patel M . Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2015; 10(12):1670-4. PMC: 4643748. DOI: 10.1097/01.JTO.0000473485.38553.f0. View

18.

Ou S, Kwak E, Siwak-Tapp C, Dy J, Bergethon K, Clark J . Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011; 6(5):942-6. DOI: 10.1097/JTO.0b013e31821528d3. View

19.

Davies K, Mahale S, Astling D, Aisner D, Le A, Hinz T . Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One. 2013; 8(12):e82236. PMC: 3862576. DOI: 10.1371/journal.pone.0082236. View

20.

Ross J, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J . The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2015; 138(4):881-90. PMC: 5049644. DOI: 10.1002/ijc.29825. View